Merck's Cancer Drug Legacy: Why This Healthcare Giant Remains a Dividend Powerhouse

Despite industry challenges, Merck has managed to chart a steady course, with its stock climbing 46% over the past year. This outperformance has caught many market observers’ attention, particularly given the headwinds the company has navigated. Revenue pressures on flagship products like Gardasil and Gardasil 9 HPV vaccines, combined with looming competitive threats, might suggest otherwise. Yet investors and analysts increasingly recognize Merck as a compelling long-term holding, especially for those prioritizing dividend income. Here’s what makes the pharmaceutical giant attractive at this juncture.

A Year of Strong Gains Despite Formidable Headwinds

The 46% surge in Merck’s share price over the trailing twelve months stands out in a challenging healthcare landscape. This rally reflects more than market enthusiasm—it signals investor confidence in the company’s strategic positioning and resilience. Despite HPV vaccine revenue declines and uncertainty surrounding its core cancer drug portfolio, Merck has demonstrated the ability to adapt and grow, reinforcing its status as a stalwart for income-seeking investors.

Keytruda Faces Competition, But Its Cancer Drug Fortress Remains Strong

Keytruda holds the crown as the world’s best-selling cancer medication, with approvals across multiple indications spanning non-small cell lung cancer (NSCLC) and beyond. However, the company faces a critical inflection point: patent protection expires in 2028. This timeline has prompted several competitors to accelerate development of rival therapies. Summit Therapeutics’ ivonescimab, for instance, demonstrated superiority over Keytruda in head-to-head trials for NSCLC patients with PD-L1 overexpression—a sobering development for Merck.

Yet Keytruda’s franchise is far from vulnerable. The company has secured approval for a subcutaneous formulation that fundamentally alters the competitive calculus. This delivery method offers faster administration with greater convenience compared to the original intravenous version, while maintaining identical therapeutic efficacy. This innovation creates a meaningful moat against challengers.

The cancer drug’s entrenched market presence, supported by extensive clinical evidence across numerous patient populations, provides a durable foundation. While “Keytruda killers” will likely gain traction in coming years, the franchise’s established footprint—particularly in NSCLC and other oncology niches—positions it to retain substantial share even amid intensifying competition. The therapy’s proven outcomes and physician familiarity offer inherent protective advantages.

Strategic Diversification: Beyond Cancer Drugs

Merck’s pipeline extends well beyond Keytruda. Recent approvals have yielded Winrevair for pulmonary arterial hypertension and Capvaxive for pneumonia vaccination. Both products are generating meaningful commercial traction, with Winrevair already achieving annual sales exceeding $1 billion. This diversification reflects Merck’s long-standing strategy of developing successive generations of therapies to counteract patent cliffs and competitive erosion.

Looking forward, the company’s research pipeline contains promising candidates, including a potential breakthrough in influenza vaccination. This innovation could reshape market dynamics in a massive therapeutic category. Such initiatives underscore Merck’s commitment to growth through sustained innovation—a playbook the healthcare leader has executed consistently over decades.

Dividend Growth and Financial Stability

For income investors, Merck’s dividend policy offers particularly compelling mechanics. The company has increased its payout over the past decade by 93.8%, demonstrating steadfast commitment to returning capital to shareholders. The current payout ratio of 45.1% leaves ample room for future dividend raises, suggesting management confidence in underlying cash generation.

The forward yield of 2.8% substantially exceeds the S&P 500 average of 1.2%, providing yield-hungry investors with a material income advantage. This differential becomes increasingly attractive in an environment where yield opportunities remain scarce.

A Long-Term Holding for Income-Focused Investors

Despite the Keytruda patent cliff looming in 2028 and ongoing challenges in the HPV vaccine segment, Merck emerges as a compelling buy-and-hold vehicle for investors with extended time horizons. The company has demonstrated its capacity to navigate disruption through strategic innovation and portfolio management.

For those seeking cancer drug exposure combined with reliable dividend growth, Merck offers a rare combination: a healthcare leader positioned at the intersection of innovation pipelines and mature profit generation. The market’s recognition of this value—reflected in recent share price appreciation—suggests that both growth and income investors have reason to maintain conviction in the company’s long-term trajectory.